Open
Do GIP/GLP-1 & amylin agonists improve costs & health-care use more than other treatments?
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
No claim has formed for this comparison yet. The trials below are registered, but none decides it.
Already under way
No registered trial that could settle this is recruiting or active.
The evidence so far
- Registered trials
- 5
- With posted results
- 1
- Published papers
- 0
Trials
- A Phase 4 Multicenter, Randomized, Open-Label, Interventional Study With Pragmatic Elements Investigating the Effectiveness of Tirzepatide Once Weekly Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes in a Real-World SettingNCT07247084
- Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular RiskNCT07096063
- Effectiveness and Safety of Tirzepatide (t.g.) in Patients Treated at the Obesity Unit of the Department of Endocrinology of the Hospital de Clínicas, Faculty of Medical Sciences, UNA: Phase 4 StudyNCT07492563
- GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot TrialNCT06162715
- The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)NCT04255433 · 1 posted result